Global Peptide Cancer Vaccine Market Growth 2024-2030

Publisher Name :
Date: 04-Jan-2024
No. of pages: 115

According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period.

The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Peptide Cancer Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Peptide Cancer Vaccine market.

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.

USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.

Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.

Key Features:

The report on Peptide Cancer Vaccine market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Peptide Cancer Vaccine market. It may include historical data, market Segmentation by Pipeline (e.g., ITK-1, GRN-1201), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Peptide Cancer Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Peptide Cancer Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Peptide Cancer Vaccine industry. This include advancements in Peptide Cancer Vaccine technology, Peptide Cancer Vaccine new entrants, Peptide Cancer Vaccine new investment, and other innovations that are shaping the future of Peptide Cancer Vaccine.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Peptide Cancer Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Peptide Cancer Vaccine product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Peptide Cancer Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Peptide Cancer Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Peptide Cancer Vaccine market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Peptide Cancer Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Peptide Cancer Vaccine market.

Market Segmentation:

Peptide Cancer Vaccine market is split by Pipeline and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Pipeline, and by Application in terms of volume and value.

Segmentation by pipeline

- ITK-1

- GRN-1201

- TPIV200

- TPIV110

- UV1

- Galinpepimut-S

- TARP 27-35

- HER-Vaxx

- Vx-001

- Others

Segmentation by application

- Breast Cancer

- Lung Cancer

- Melanoma

- Prostate Cancer

- Others

This report also splits the market by region:

- Americas

- - United States

- - Canada

- - Mexico

- - Brazil

- APAC

- - China

- - Japan

- - Korea

- - Southeast Asia

- - India

- - Australia

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- Middle East & Africa

- - Egypt

- - South Africa

- - Israel

- - Turkey

- - GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

- Boston Biomedical

- Ultimovacs

- BrightPath Biotherapeutics

- TapImmune

- Immatics

- Sellas

- Imugene

- VAXON Biotech

- Generex Biotechnology

- ISA Pharmaceuticals

- OncoTherapy Science

Key Questions Addressed in this Report

What is the 10-year outlook for the global Peptide Cancer Vaccine market?

What factors are driving Peptide Cancer Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Peptide Cancer Vaccine market opportunities vary by end market size?

How does Peptide Cancer Vaccine break out pipeline, application?

Global Peptide Cancer Vaccine Market Growth 2024-2030

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide Cancer Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Peptide Cancer Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Peptide Cancer Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Peptide Cancer Vaccine Segment by Pipeline
2.2.1 ITK-1
2.2.2 GRN-1201
2.2.3 TPIV200
2.2.4 TPIV110
2.2.5 UV1
2.2.6 Galinpepimut-S
2.2.7 TARP 27-35
2.2.8 HER-Vaxx
2.2.9 Vx-001
2.2.10 Others
2.3 Peptide Cancer Vaccine Sales by Pipeline
2.3.1 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
2.3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Pipeline (2019-2024)
2.3.3 Global Peptide Cancer Vaccine Sale Price by Pipeline (2019-2024)
2.4 Peptide Cancer Vaccine Segment by Application
2.4.1 Breast Cancer
2.4.2 Lung Cancer
2.4.3 Melanoma
2.4.4 Prostate Cancer
2.4.5 Others
2.5 Peptide Cancer Vaccine Sales by Application
2.5.1 Global Peptide Cancer Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Peptide Cancer Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Peptide Cancer Vaccine Sale Price by Application (2019-2024)
3 Global Peptide Cancer Vaccine by Company
3.1 Global Peptide Cancer Vaccine Breakdown Data by Company
3.1.1 Global Peptide Cancer Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Peptide Cancer Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Peptide Cancer Vaccine Revenue by Company (2019-2024)
3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Peptide Cancer Vaccine Sale Price by Company
3.4 Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Cancer Vaccine Product Location Distribution
3.4.2 Players Peptide Cancer Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Peptide Cancer Vaccine by Geographic Region
4.1 World Historic Peptide Cancer Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Peptide Cancer Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Peptide Cancer Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Peptide Cancer Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Peptide Cancer Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Peptide Cancer Vaccine Sales Growth
4.4 APAC Peptide Cancer Vaccine Sales Growth
4.5 Europe Peptide Cancer Vaccine Sales Growth
4.6 Middle East & Africa Peptide Cancer Vaccine Sales Growth
5 Americas
5.1 Americas Peptide Cancer Vaccine Sales by Country
5.1.1 Americas Peptide Cancer Vaccine Sales by Country (2019-2024)
5.1.2 Americas Peptide Cancer Vaccine Revenue by Country (2019-2024)
5.2 Americas Peptide Cancer Vaccine Sales by Pipeline
5.3 Americas Peptide Cancer Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Cancer Vaccine Sales by Region
6.1.1 APAC Peptide Cancer Vaccine Sales by Region (2019-2024)
6.1.2 APAC Peptide Cancer Vaccine Revenue by Region (2019-2024)
6.2 APAC Peptide Cancer Vaccine Sales by Pipeline
6.3 APAC Peptide Cancer Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Peptide Cancer Vaccine by Country
7.1.1 Europe Peptide Cancer Vaccine Sales by Country (2019-2024)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Country (2019-2024)
7.2 Europe Peptide Cancer Vaccine Sales by Pipeline
7.3 Europe Peptide Cancer Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide Cancer Vaccine by Country
8.1.1 Middle East & Africa Peptide Cancer Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline
8.3 Middle East & Africa Peptide Cancer Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine
10.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
10.4 Industry Chain Structure of Peptide Cancer Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Cancer Vaccine Distributors
11.3 Peptide Cancer Vaccine Customer
12 World Forecast Review for Peptide Cancer Vaccine by Geographic Region
12.1 Global Peptide Cancer Vaccine Market Size Forecast by Region
12.1.1 Global Peptide Cancer Vaccine Forecast by Region (2025-2030)
12.1.2 Global Peptide Cancer Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Peptide Cancer Vaccine Forecast by Pipeline
12.7 Global Peptide Cancer Vaccine Forecast by Application
13 Key Players Analysis
13.1 Boston Biomedical
13.1.1 Boston Biomedical Company Information
13.1.2 Boston Biomedical Peptide Cancer Vaccine Product Portfolios and Specifications
13.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Boston Biomedical Main Business Overview
13.1.5 Boston Biomedical Latest Developments
13.2 Ultimovacs
13.2.1 Ultimovacs Company Information
13.2.2 Ultimovacs Peptide Cancer Vaccine Product Portfolios and Specifications
13.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Ultimovacs Main Business Overview
13.2.5 Ultimovacs Latest Developments
13.3 BrightPath Biotherapeutics
13.3.1 BrightPath Biotherapeutics Company Information
13.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolios and Specifications
13.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 BrightPath Biotherapeutics Main Business Overview
13.3.5 BrightPath Biotherapeutics Latest Developments
13.4 TapImmune
13.4.1 TapImmune Company Information
13.4.2 TapImmune Peptide Cancer Vaccine Product Portfolios and Specifications
13.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 TapImmune Main Business Overview
13.4.5 TapImmune Latest Developments
13.5 Immatics
13.5.1 Immatics Company Information
13.5.2 Immatics Peptide Cancer Vaccine Product Portfolios and Specifications
13.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Immatics Main Business Overview
13.5.5 Immatics Latest Developments
13.6 Sellas
13.6.1 Sellas Company Information
13.6.2 Sellas Peptide Cancer Vaccine Product Portfolios and Specifications
13.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sellas Main Business Overview
13.6.5 Sellas Latest Developments
13.7 Imugene
13.7.1 Imugene Company Information
13.7.2 Imugene Peptide Cancer Vaccine Product Portfolios and Specifications
13.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Imugene Main Business Overview
13.7.5 Imugene Latest Developments
13.8 VAXON Biotech
13.8.1 VAXON Biotech Company Information
13.8.2 VAXON Biotech Peptide Cancer Vaccine Product Portfolios and Specifications
13.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 VAXON Biotech Main Business Overview
13.8.5 VAXON Biotech Latest Developments
13.9 Generex Biotechnology
13.9.1 Generex Biotechnology Company Information
13.9.2 Generex Biotechnology Peptide Cancer Vaccine Product Portfolios and Specifications
13.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Generex Biotechnology Main Business Overview
13.9.5 Generex Biotechnology Latest Developments
13.10 ISA Pharmaceuticals
13.10.1 ISA Pharmaceuticals Company Information
13.10.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolios and Specifications
13.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 ISA Pharmaceuticals Main Business Overview
13.10.5 ISA Pharmaceuticals Latest Developments
13.11 OncoTherapy Science
13.11.1 OncoTherapy Science Company Information
13.11.2 OncoTherapy Science Peptide Cancer Vaccine Product Portfolios and Specifications
13.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 OncoTherapy Science Main Business Overview
13.11.5 OncoTherapy Science Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Peptide Cancer Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Peptide Cancer Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of ITK-1
Table 4. Major Players of GRN-1201
Table 5. Major Players of TPIV200
Table 6. Major Players of TPIV110
Table 7. Major Players of UV1
Table 8. Major Players of Galinpepimut-S
Table 9. Major Players of TARP 27-35
Table 10. Major Players of HER-Vaxx
Table 11. Major Players of Vx-001
Table 12. Major Players of Others
Table 13. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Units)
Table 14. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Table 15. Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & ($ million)
Table 16. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2024)
Table 17. Global Peptide Cancer Vaccine Sale Price by Pipeline (2019-2024) & (USD/Unit)
Table 18. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Units)
Table 19. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Table 20. Global Peptide Cancer Vaccine Revenue by Application (2019-2024)
Table 21. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 22. Global Peptide Cancer Vaccine Sale Price by Application (2019-2024) & (USD/Unit)
Table 23. Global Peptide Cancer Vaccine Sales by Company (2019-2024) & (K Units)
Table 24. Global Peptide Cancer Vaccine Sales Market Share by Company (2019-2024)
Table 25. Global Peptide Cancer Vaccine Revenue by Company (2019-2024) ($ Millions)
Table 26. Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2024)
Table 27. Global Peptide Cancer Vaccine Sale Price by Company (2019-2024) & (USD/Unit)
Table 28. Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution and Sales Area
Table 29. Players Peptide Cancer Vaccine Products Offered
Table 30. Peptide Cancer Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global Peptide Cancer Vaccine Sales by Geographic Region (2019-2024) & (K Units)
Table 34. Global Peptide Cancer Vaccine Sales Market Share Geographic Region (2019-2024)
Table 35. Global Peptide Cancer Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 36. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 37. Global Peptide Cancer Vaccine Sales by Country/Region (2019-2024) & (K Units)
Table 38. Global Peptide Cancer Vaccine Sales Market Share by Country/Region (2019-2024)
Table 39. Global Peptide Cancer Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 40. Global Peptide Cancer Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 41. Americas Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Americas Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 43. Americas Peptide Cancer Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 44. Americas Peptide Cancer Vaccine Revenue Market Share by Country (2019-2024)
Table 45. Americas Peptide Cancer Vaccine Sales by Type (2019-2024) & (K Units)
Table 46. Americas Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Units)
Table 47. APAC Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Units)
Table 48. APAC Peptide Cancer Vaccine Sales Market Share by Region (2019-2024)
Table 49. APAC Peptide Cancer Vaccine Revenue by Region (2019-2024) & ($ Millions)
Table 50. APAC Peptide Cancer Vaccine Revenue Market Share by Region (2019-2024)
Table 51. APAC Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Units)
Table 52. APAC Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Units)
Table 53. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 54. Europe Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 55. Europe Peptide Cancer Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 56. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2019-2024)
Table 57. Europe Peptide Cancer Vaccine Sales by Type (2019-2024) & (K Units)
Table 58. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Units)
Table 59. Middle East & Africa Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 60. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 61. Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 62. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country (2019-2024)
Table 63. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Units)
Table 64. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of Peptide Cancer Vaccine
Table 66. Key Market Challenges & Risks of Peptide Cancer Vaccine
Table 67. Key Industry Trends of Peptide Cancer Vaccine
Table 68. Peptide Cancer Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Peptide Cancer Vaccine Distributors List
Table 71. Peptide Cancer Vaccine Customer List
Table 72. Global Peptide Cancer Vaccine Sales Forecast by Region (2025-2030) & (K Units)
Table 73. Global Peptide Cancer Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 74. Americas Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Americas Peptide Cancer Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. APAC Peptide Cancer Vaccine Sales Forecast by Region (2025-2030) & (K Units)
Table 77. APAC Peptide Cancer Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 78. Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 79. Europe Peptide Cancer Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 80. Middle East & Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 81. Middle East & Africa Peptide Cancer Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 82. Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2025-2030) & (K Units)
Table 83. Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2025-2030) & ($ Millions)
Table 84. Global Peptide Cancer Vaccine Sales Forecast by Application (2025-2030) & (K Units)
Table 85. Global Peptide Cancer Vaccine Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 86. Boston Biomedical Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 87. Boston Biomedical Peptide Cancer Vaccine Product Portfolios and Specifications
Table 88. Boston Biomedical Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Boston Biomedical Main Business
Table 90. Boston Biomedical Latest Developments
Table 91. Ultimovacs Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 92. Ultimovacs Peptide Cancer Vaccine Product Portfolios and Specifications
Table 93. Ultimovacs Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Ultimovacs Main Business
Table 95. Ultimovacs Latest Developments
Table 96. BrightPath Biotherapeutics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 97. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolios and Specifications
Table 98. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. BrightPath Biotherapeutics Main Business
Table 100. BrightPath Biotherapeutics Latest Developments
Table 101. TapImmune Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 102. TapImmune Peptide Cancer Vaccine Product Portfolios and Specifications
Table 103. TapImmune Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. TapImmune Main Business
Table 105. TapImmune Latest Developments
Table 106. Immatics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 107. Immatics Peptide Cancer Vaccine Product Portfolios and Specifications
Table 108. Immatics Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Immatics Main Business
Table 110. Immatics Latest Developments
Table 111. Sellas Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 112. Sellas Peptide Cancer Vaccine Product Portfolios and Specifications
Table 113. Sellas Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Sellas Main Business
Table 115. Sellas Latest Developments
Table 116. Imugene Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 117. Imugene Peptide Cancer Vaccine Product Portfolios and Specifications
Table 118. Imugene Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Imugene Main Business
Table 120. Imugene Latest Developments
Table 121. VAXON Biotech Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 122. VAXON Biotech Peptide Cancer Vaccine Product Portfolios and Specifications
Table 123. VAXON Biotech Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. VAXON Biotech Main Business
Table 125. VAXON Biotech Latest Developments
Table 126. Generex Biotechnology Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 127. Generex Biotechnology Peptide Cancer Vaccine Product Portfolios and Specifications
Table 128. Generex Biotechnology Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Generex Biotechnology Main Business
Table 130. Generex Biotechnology Latest Developments
Table 131. ISA Pharmaceuticals Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 132. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolios and Specifications
Table 133. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. ISA Pharmaceuticals Main Business
Table 135. ISA Pharmaceuticals Latest Developments
Table 136. OncoTherapy Science Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 137. OncoTherapy Science Peptide Cancer Vaccine Product Portfolios and Specifications
Table 138. OncoTherapy Science Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. OncoTherapy Science Main Business
Table 140. OncoTherapy Science Latest Developments
List of Figures
Figure 1. Picture of Peptide Cancer Vaccine
Figure 2. Peptide Cancer Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Cancer Vaccine Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Peptide Cancer Vaccine Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Peptide Cancer Vaccine Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of ITK-1
Figure 10. Product Picture of GRN-1201
Figure 11. Product Picture of TPIV200
Figure 12. Product Picture of TPIV110
Figure 13. Product Picture of UV1
Figure 14. Product Picture of Galinpepimut-S
Figure 15. Product Picture of TARP 27-35
Figure 16. Product Picture of HER-Vaxx
Figure 17. Product Picture of Vx-001
Figure 18. Product Picture of Others
Figure 19. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2023
Figure 20. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2024)
Figure 21. Peptide Cancer Vaccine Consumed in Breast Cancer
Figure 22. Global Peptide Cancer Vaccine Market: Breast Cancer (2019-2024) & (K Units)
Figure 23. Peptide Cancer Vaccine Consumed in Lung Cancer
Figure 24. Global Peptide Cancer Vaccine Market: Lung Cancer (2019-2024) & (K Units)
Figure 25. Peptide Cancer Vaccine Consumed in Melanoma
Figure 26. Global Peptide Cancer Vaccine Market: Melanoma (2019-2024) & (K Units)
Figure 27. Peptide Cancer Vaccine Consumed in Prostate Cancer
Figure 28. Global Peptide Cancer Vaccine Market: Prostate Cancer (2019-2024) & (K Units)
Figure 29. Peptide Cancer Vaccine Consumed in Others
Figure 30. Global Peptide Cancer Vaccine Market: Others (2019-2024) & (K Units)
Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Application (2023)
Figure 32. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2023
Figure 33. Peptide Cancer Vaccine Sales Market by Company in 2023 (K Units)
Figure 34. Global Peptide Cancer Vaccine Sales Market Share by Company in 2023
Figure 35. Peptide Cancer Vaccine Revenue Market by Company in 2023 ($ Million)
Figure 36. Global Peptide Cancer Vaccine Revenue Market Share by Company in 2023
Figure 37. Global Peptide Cancer Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 38. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region in 2023
Figure 39. Americas Peptide Cancer Vaccine Sales 2019-2024 (K Units)
Figure 40. Americas Peptide Cancer Vaccine Revenue 2019-2024 ($ Millions)
Figure 41. APAC Peptide Cancer Vaccine Sales 2019-2024 (K Units)
Figure 42. APAC Peptide Cancer Vaccine Revenue 2019-2024 ($ Millions)
Figure 43. Europe Peptide Cancer Vaccine Sales 2019-2024 (K Units)
Figure 44. Europe Peptide Cancer Vaccine Revenue 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Peptide Cancer Vaccine Sales 2019-2024 (K Units)
Figure 46. Middle East & Africa Peptide Cancer Vaccine Revenue 2019-2024 ($ Millions)
Figure 47. Americas Peptide Cancer Vaccine Sales Market Share by Country in 2023
Figure 48. Americas Peptide Cancer Vaccine Revenue Market Share by Country in 2023
Figure 49. Americas Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Figure 50. Americas Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Figure 51. United States Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 52. Canada Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 53. Mexico Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 54. Brazil Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 55. APAC Peptide Cancer Vaccine Sales Market Share by Region in 2023
Figure 56. APAC Peptide Cancer Vaccine Revenue Market Share by Regions in 2023
Figure 57. APAC Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Figure 58. APAC Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Figure 59. China Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 60. Japan Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 61. South Korea Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 62. Southeast Asia Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 63. India Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 64. Australia Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 65. China Taiwan Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 66. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2023
Figure 67. Europe Peptide Cancer Vaccine Revenue Market Share by Country in 2023
Figure 68. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Figure 69. Europe Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Figure 70. Germany Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 71. France Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 72. UK Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 73. Italy Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 74. Russia Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 75. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country in 2023
Figure 76. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country in 2023
Figure 77. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Figure 78. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Figure 79. Egypt Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 80. South Africa Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 81. Israel Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 82. Turkey Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 83. GCC Country Peptide Cancer Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 84. Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine in 2023
Figure 85. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 86. Industry Chain Structure of Peptide Cancer Vaccine
Figure 87. Channels of Distribution
Figure 88. Global Peptide Cancer Vaccine Sales Market Forecast by Region (2025-2030)
Figure 89. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Region (2025-2030)
Figure 90. Global Peptide Cancer Vaccine Sales Market Share Forecast by Pipeline (2025-2030)
Figure 91. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Pipeline (2025-2030)
Figure 92. Global Peptide Cancer Vaccine Sales Market Share Forecast by Application (2025-2030)
Figure 93. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Application (2025-2030)
  • Global BCG Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Peptide Cancer Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
  • Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
  • Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......
  • Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
  • Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
  • Global BCG Vaccine Market Research Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Infectious Vaccine Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs